October 25, 2018 - "The patent outcome enables us to intensify our business development and M&A efforts of broadening our late-stage and commercial product portfolio"
DECEMBER 13, 2018 – Orexo will get back the rights for Zubsolv ex US from its partner Mundipharma. The Company will now initiate formal negotiations with several interested parties enabling to create the best prerequisites for Zubsolv to reach its full potential globally.
Orexo´s pipeline contains projects in different development phases, with a primary therapeutic focus around opioid addiction in all phases, from prevention to treatment. One objective is to increase the pipeline with clinical stage projects. Read more about the development projects below.
Orexo positiva till FDA-satsningar för nya läkemedel mot opioidöverdoser - Lena Wange IR & Communications Mgr komme… https://t.co/q71h5JrRP1